Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.

We describe a patient with invasive pulmonary aspergillosis on extracorporeal membrane oxygenation therapy in which therapeutic drug monitoring and individualization of therapy by measuring voriconazole plasma concentrations were performed.

[1]  J. Donnelly,et al.  Therapeutic Drug Monitoring of Voriconazole , 2008, Therapeutic drug monitoring.

[2]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Thierry Buclin,et al.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Arnold,et al.  Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment , 2007, Intensive Care Medicine.

[5]  J. Burhenne,et al.  Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy , 2006, BMC clinical pharmacology.

[6]  Laurance Lequier,et al.  Extracorporeal Life Support in Pediatric and Neonatal Critical Care: A Review , 2004, Journal of intensive care medicine.

[7]  T. Buclin,et al.  Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient. , 2004, The Journal of antimicrobial chemotherapy.

[8]  M. Karlsson,et al.  Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration , 2004, Antimicrobial Agents and Chemotherapy.

[9]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[10]  M. Buck.  Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation , 2003, Clinical pharmacokinetics.

[11]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[12]  J. Klaessens,et al.  Hemodynamic changes during opening of the bridge in venoarterial extracorporeal membrane oxygenation , 2001, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.